CraigMitchellZaidmanMD

Child Neurology • Saint Louis, MO

Assistant Professor, Neurology, Washington University School of Medicine

Join to view full profile

Dr. Zaidman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zaidman's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 314-362-1408

Fax+1 314-362-3752

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Clinical Neurophysiology, 2007 - 2008
Washington University/B-JH/SLCH ConsortiumFellowship, Child Neurology, 2005 - 2007
Brown UniversityResidency, Neurology, 2003 - 2004
Brown UniversityResidency, Pediatrics, 2001 - 2003
University of Virginia School of MedicineClass of 2001

Certifications & Licensure

IL State Medical License 2021 - 2026
MO State Medical License 2007 - 2026
RI State Medical License 2003 - 2006
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
American Board of Psychiatry and Neurology Clinical Neurophysiology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Clinical Trials

Spinraza in Adult Spinal Muscular Atrophy Start of enrollment: 2018 Aug 16
Recruiting
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) Start of enrollment: 2018 Sep 25
Recruiting

Publications & Presentations

PubMed

Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study.
Hugh J McMillan, Giovanni Baranello, Michelle A Farrar, Craig M Zaidman, Teresa Moreno
Neurology. 2025-01-28
Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy.
Rachael A Potter, Ida H Moeller, Sohrab Khan, Hélène Haegel, Andreas Hollenstein
Scientific Reports. 2025-01-02
7 citations
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
Jerry R Mendell, Francesco Muntoni, Craig M McDonald, Eugenio M Mercuri, Emma Ciafaloni
Nature Medicine. 2025-01-01

Journal Articles

Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Paula R Clemens, Vamshi K Rao, Craig M Zaidman, JAMA Neurology
CANOMAD and Other Chronic Ataxic Neuropathies with Disialosyl Antibodies (CANDA)
R Brian Sommerville, Craig M Zaidman, Glenn Lopate, Alan Pestronk, Conrad C Weihl, Robert C Bucelli, Journal of Neurology

Authored Content

Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 SkippingMay 2020

Press Mentions

Washington University Researchers to Present Findings at National Neurology MeetingOctober 3rd, 2019
Duchenne Muscular Dystrophy Gene TherapyJuly 4th, 2024